CME: Because You Care About Your Patients With ROS1+ NSCLC: Recent Revolutions in Treatment

Because You Care About Your Patients With ROS1+ NSCLC: Recent Revolutions in Treatment

Because You Care About Your Patients With ROS1+ NSCLC: Recent Revolutions in Treatment
RestartResume

What’s the most recent clinical data saying about how to approach the treatment of ROS1+ metastatic non-small cell lung cancer?

Available credits: 0.50

Time to complete: 30 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The discovery of predictive biomarkers, including ROS1 rearrangements, has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. First-line therapy options for ROS1 rearrangement–positive metastatic NSCLC now include crizotinib, entrectinib, and ceritinib, with the NCCN recommending crizotinib and entrectinib as preferred agents. Additional agents are being studied to improve treatment outcomes of patients with ROS1 rearrangement–positive NSCLC that becomes resistant to available therapies.

    This activity reviews the most recent clinical data and evidence-based updates and provides expert insights on the treatment of ROS1+ metastatic NSCLC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Integrate the use of currently available treatment options for ROS1 rearrangement–positive metastatic non–small cell lung cancer according to guideline recommendations
    • Identify mechanisms of resistance to crizotinib and the need for development of novel ROS1 inhibitors
    • Assess recent data supporting the use of investigational therapies in development for the treatment of ROS1 rearrangement–positive non–small cell lung cancer
  • Target Audience

    This activity is intended for medical oncologists, thoracic oncologists, pathologists, pulmonologists, fellows, physician assistants, nurse practitioners, oncology nurses, and pharmacists involved in the care of patients with ROS1+ NSCLC.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Alexander Drilon, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Roche/Genentech/Ignyta; Loxo/Bayer/Lilly; Takeda Oncology/Ariad/Millenium; Turning Point Therapeutics; Inc; AstraZeneca Pharmaceuticals LP; Pfizer, Inc; Blueprint Medicines; Helsinn Therapeutics (US) Inc; BeiGene LTD; BerGenBio; Hengrui Therapeutics, Inc; Exelixis, Inc; Tyra Biosciences; Verastem Inc; MORE Health; and AbbVie. Research grant: Foundation Medicine. Research support to Memorial Sloan Kettering Cancer Center: Pfizer, Inc; Exelixis, Inc; GlaxoSmithKline; Teva Pharmaceuticals; Taiho Pharmaceutical Co, Ltd; and Pharma Mar, SA. Royalty: Wolters Kluwer. Other: Food and BeverageI Merck & Co, Inc; and PUMA Biotechnology. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS;  and Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. . Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation and Credit Designation Statements

    CONTINUING MEDICAL EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 03/29/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.50 contact hour of continuing pharmacy education credit JA4008106-0000-20-007-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.50 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Commercial Support

    This educational activity is supported by an educational grant from Genentech.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

Facebook Comments

Register

We’re glad to see you’re enjoying Rheumatology Academy…
but how about a more personalized experience?

Register for free